TNF and inflammatory bowel disease: In concurrence with the reported increase in the incidence of pediatric IBD [30], the rate of biologic therapy and, specifically, anti-TNF-α agents, is increasing worldwide among both adults and children [31–34] and is now the cornerstone in the treatment of IBD.